The ATB-Raisin antibiotic (ATB) usage monitoring system contributes to the appropriate use of antibiotics. Its objectives are to enable each healthcare facility (HCF) to describe and analyze its antibiotic usage in comparison with a comparable group and to cross-reference this data with bacterial resistance data. Systemic ATBs in class J01 of the Anatomical Therapeutic Chemical (ATC) classification, rifampicin and oral imidazoles, as well as systemic antifungals in class J02, dispensed during inpatient stays, were expressed in defined daily doses (DDD) and reported according to national and World Health Organization recommendations (ATC-DDD system, 2012). Resistance data were collected for seven bacteria/antibiotic pairs. The 1,411 participating healthcare facilities in 2012 accounted for 66% of hospital days (HD) and had consumed 374 DDD/1,000 HD. The most commonly used antibiotics were the amoxicillin-clavulanic acid combination (32%), amoxicillin (17%), and ceftriaxone (5%). Median antibiotic consumption ranged from 52 DDD/1,000 HD in psychiatric hospitals to 550 in military training hospitals. Variations were observed across specialties, ranging from 62 DDD/1,000 HD in psychiatry to 1,506 in intensive care. In the 565 healthcare facilities that have participated annually since 2008, consumption in 2012 remained stable compared to 2011, whereas it had increased by approximately 7% between 2008 and 2012. Resistance data were consistent with those from specific networks. Antifungal consumption was twice as high in hematology (340 DDJ/1,000 patient-days) as in intensive care (163 DDJ/1,000 patient-days). Network-based surveillance allows each healthcare facility to assess its position relative to others, exchange information on practices and organizational structures, and track evolving trends. Analysis of antibiotic consumption should be supplemented by an evaluation of practices. (R.A.)